A significant increase in PPARα target gene expression in the liver (Figure 2) and an elevation of the plasma FGF21 concentration (Figure 3) was observed after systemic administration of pemafibrate, which is consistent with a previous report of pemafibrate increasing FGF21 expression in patients with type 2 diabetes with hypertriglyceridemia and in high fat diet mice [24,25]. Here, FGF21 is linked to hypertriglyceridemia.